| 3.12 0.15 (5.05%) | 05-29 13:23 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.2 |
1-year : | 4.91 |
| Resists | First : | 3.59 |
Second : | 4.2 |
| Pivot price | 3.02  |
|||
| Supports | First : | 2.99 |
Second : | 2.62 |
| MAs | MA(5) : | 2.89 |
MA(20) : | 3.09 |
| MA(100) : | 4.1 |
MA(250) : | 5.14 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 47.1 |
D(3) : | 27.7 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 10.8 | Low : | 2.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XCUR ] has closed below upper band by 26.3%. Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3 - 3.02 | 3.02 - 3.03 |
| Low: | 2.73 - 2.74 | 2.74 - 2.76 |
| Close: | 2.95 - 2.97 | 2.97 - 2.99 |
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Tue, 19 May 2026
Exicure Inc stock (US30205M1027): micro-cap biotech restructures after Nasdaq delisting - AD HOC NEWS
Fri, 15 May 2026
Exicure (XCUR) delays Q1 2026 10-Q; prelim net loss $1.83M - Stock Titan
Thu, 23 Apr 2026
Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies - Quiver Quantitative
Tue, 07 Apr 2026
Is Exicure (XCUR) Stock Gaining Momentum | Price at $3.84, Down 4.24% - High Volume Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Sat, 28 Mar 2026
Exicure, Inc. Files Form 8-K with SEC – Company Info, Stock Symbol XCUR, and NASDAQ Listing Details - Minichart
Wed, 25 Mar 2026
Exicure 10-K: Revenue $0.0M, EPS $(0.79) — net loss narrows to $(4.95)M - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 35.3 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 52 (K) |
| Shares Short P.Month | 58 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.5 % |
| Return on Equity (ttm) | -92.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.52 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -4.09 |
| PEG Ratio | 0 |
| Price to Book value | 5.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|